Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 340 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug-Related Side Effects and Adverse Reactions Clear all
Terminated Phase 2 Interventional

Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose

NCT05517668
View directory record Official record
Conditions
Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning, Drug-induced Liver Injury, Liver Failure, Liver Toxicity
Interventions
Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP)
Drug
Lead sponsor
Richard Dart, MD, PhD
Other
Eligibility
10 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Completed No phase listed Observational

Taste of Medicines in Children

NCT04220918
View directory record Official record
Conditions
Medication Adherence, Medication Reaction
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years to 12 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

NCT00039481
View directory record Official record
Conditions
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
oblimersen sodium, dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, filgrastim, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Sep 28, 2026, 4:52 AM EDT
Terminated Phase 4 Interventional

Pain Control After Minimally Invasive Coronary Artery Bypass Grafting

NCT01770236
View directory record Official record
Conditions
Postoperative Pain, Medication Side Effects, Narcotic Requirement
Interventions
IV acetaminophen
Drug
Lead sponsor
Gundersen Lutheran Medical Foundation
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

NCT01205503
View directory record Official record
Conditions
Breast Cancer, Non-Hodgkin's Lymphoma
Interventions
Mesna, Saline, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Mara Chambers
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Sep 28, 2026, 4:52 AM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Adverse Drug Events With PatientSite

NCT00140504
View directory record Official record
Conditions
Adverse Drug Event
Interventions
Medcheck message
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Sep 28, 2026, 4:52 AM EDT
Not yet recruiting Not applicable Interventional

AIManage Using an AI-driven CDS and Chatbot

NCT07546357
View directory record Official record
Conditions
Diabetes, Obesity, Medication Side Effects
Interventions
AIManage
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Active, not recruiting Not applicable Interventional

nCCR for Chemotherapy Related Cognitive Impairment Randomized Study

NCT05283629
View directory record Official record
Conditions
Chemo-brain, Chemotherapy-Related Cognitive Impairment
Interventions
Neuroplasticity-based Computerized Cognitive Remediation, Active Control Condition
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
35 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Recruiting Phase 3 Interventional

Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge

NCT06303128
View directory record Official record
Conditions
Penicillin Allergy
Interventions
Amoxicillin 250 MG, Placebo, Amoxicillin 62.5mg, Amoxicillin 187.5mg
Drug
Lead sponsor
James Tarbox, MD
Other
Eligibility
18 Years to 89 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

NCT00198458
View directory record Official record
Conditions
Drug Hypersensitivity
Interventions
Vitrase
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2013 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

NCT01848457
View directory record Official record
Conditions
Osteosarcoma, Nephrotoxicity, Ototoxicity
Interventions
Pantoprazole, High-dose methotrexate infusion duration
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

NCT01548690
View directory record Official record
Conditions
Acute Liver Failure, Acute Liver Injury
Interventions
Ornithine Phenylacetate
Drug
Lead sponsor
William Lee
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 28, 2026, 4:52 AM EDT
Withdrawn Phase 2 Interventional

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

NCT04713202
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoid Syndrome, Diarrhea
Interventions
Telotristat ethyl, Peptide Receptor Radionuclide Therapy, Placebo
Drug · Other
Lead sponsor
Chandrikha Chandrasekhara
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 3 Interventional

NATIENS: Optimal Management and Mechanisms of SJS/TEN

NCT02987257
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Interventions
Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer

NCT02290834
View directory record Official record
Conditions
Impaired Cognition, Chemo-brain, Breast Cancer
Interventions
Cognitive, functional and subjective assessments, MRI, PET Scan
Other · Device · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:

NCT06322238
View directory record Official record
Conditions
Pharmacogenomic Drug Interaction, Side Effect of Drug, Ineffective Drug Action, Drug Metabolism, Poor, CYP2D6-Related, Drug Metabolism, Poor, CYP2C19-Related
Interventions
PGx panel test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 2 Interventional

Topical Antiperspirant for Hand-Foot Syndrome

NCT00213993
View directory record Official record
Conditions
Palmar-plantar Erythrodysesthesia
Interventions
antiperspirant
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 28, 2026, 4:52 AM EDT
Terminated Early Phase 1 Interventional

Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity

NCT04044872
View directory record Official record
Conditions
Thoracic Cancer, Left Sided Breast Cancer
Interventions
[1-13C]pyruvate along with MRI imaging
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Challenges Without Prior Skin Testing

NCT03158831
View directory record Official record
Conditions
Drug Hypersensitivity, Penicillin Allergy, Antibiotic Allergy
Interventions
Placebo-Controlled Graded Drug Challenge
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
7 Years and older
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Sep 28, 2026, 4:52 AM EDT
Completed No phase listed Observational Results available

Defining Normal Postoperative Magnetic Resonance Imaging After Total Knee Arthroplasty

NCT04821245
View directory record Official record
Conditions
Local Anesthetic Complication, Local Anesthetic Drug Adverse Reaction
Interventions
Not listed
Lead sponsor
Benaroya Research Institute
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Sep 28, 2026, 4:52 AM EDT
Recruiting No phase listed Observational

Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure

NCT04262830
View directory record Official record
Conditions
Cardiotoxicity, Pediatric Cancer, Heart Failure
Interventions
Cardiac magnetic resonance imaging (MRI), Accelerometer physical activity monitoring
Diagnostic Test · Other
Lead sponsor
Hari Narayan
Other
Eligibility
13 Years to 39 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

NCT04196777
View directory record Official record
Conditions
Urologic Diseases, Antibacterial Drug Adverse Reaction
Interventions
Audit-and-feedback
Behavioral
Lead sponsor
Iowa City Veterans Affairs Medical Center
Federal
Eligibility
Not listed
Enrollment
525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Gainesville, Florida • Iowa City, Iowa • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 28, 2026, 4:52 AM EDT
Completed No phase listed Observational

SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial

NCT00002900
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
management of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
105
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 28, 2026, 4:52 AM EDT